Antimalarial preclinical drug development: A single oral dose of a 5-carbon-linked trioxane dimer plus mefloquine cures malaria-infected mice
Document Type
Journal Article
Publication Date
2-1-2010
Journal
Drug Development Research
Volume
71
Issue
1
DOI
10.1002/ddr.20350
Keywords
Antimalarial chemotherapy; Artemisinin combination therapy (ACT); Single oral dose ACT cure; Trioxane dimers
Abstract
Three new 5-carbon-linked trioxane dimer carboxylate esters have been prepared from the natural trioxane, artemisinin, in only three steps and 40-50% overall yields. Each one of these new chemical entities is at least as efficacious as the clinically used trioxane antimalarial drug artemether when combined with mefloquine hydrochloride in a low single oral dose cure. © 2009 Wiley-Liss, Inc.
APA Citation
Moon, D., Singhal, V., Kumar, N., Shapiro, T., & Posner, G. (2010). Antimalarial preclinical drug development: A single oral dose of a 5-carbon-linked trioxane dimer plus mefloquine cures malaria-infected mice. Drug Development Research, 71 (1). http://dx.doi.org/10.1002/ddr.20350